In general, financial media has been more optimistic on the outlook of United Therapeutics Corporation. After applying our sentiment algorithms to thousands of headlines, Contextuall established that the company's headlines have been significantly more positive, especially when compared to industry competitors.
Table Summary: Sentiment Analysis of Recent Headlines
|% Positive Headlines||17.39||1|
|% Negative Headlines||34.78||66|
|% Neutral Headlines||47.83||33|
Sample of Recent Headlines Processed by Our Sentiment Algorithms, Classified as Positive (Access Stock Sentiment Analysis Here)
- United Therapeutics Moves Up In Market Cap Rank, Passing United States Steel
- United Reaches New 52-Week High (NASDAQ:UTHR)
- Programmed Insider Buying? Yes, at Insmed and United Therapeutics
- United Therapeutics Announces Collaboration With Ascendis Pharma To Develop S...
- United Stock Hits New 52-Week High (UTHR)
- United Therapeutics Near Top Of Strong Industry Group
Sample of Recent Headlines Processed by Our Sentiment Algorithms, Classified as Negative (Access Stock Sentiment Analysis Here)
- United Therapeutics Can't Stop Getting Rejected
- FDA again rejects United Therapeutics application
- United Therapeutics Falls After Hypertension Pill Rejected
- FDA rejects new United Therapeutics drug
- United Therapeutics: FDA again rejects drug
- United Therapeutics Could Lose The Battle For PAH Therapies
- United Therapeutics Corporation (UTHR): Today's Featured Health Care Laggard
- United Therapeutics Files Lawsuit Against Sandoz For Infringement Of Remoduli...
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.